This much improved growth outlook comes as welcome news after two years of actual sales stagnation. While the patent cliff is now but a distant memory, a new debate over drug pricing is stirring up controversy. This will only intensify as the industry continues to shift away from primary care and new technology waves offer innovative products that potentially take costs out of healthcare, says Paul Hills, report author and Evaluate’s head of operations.
The infographic above is brought to you from EvaluatePharma. If you're having trouble seeing the infographic, click here.